These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22773165)

  • 61. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
    Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
    Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist.
    Xu Y; Miao X; Ravenstijn P; Hijzen A; Schmidt ME; Nandy P; Zhou H
    Clin Transl Sci; 2020 Mar; 13(2):309-317. PubMed ID: 31642608
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).
    Hodé Y; Reimold M; Demazières A; Reischl G; Bayle F; Nuss P; Hameg A; Dib M; Macher JP
    Psychopharmacology (Berl); 2005 Jul; 180(2):377-84. PubMed ID: 15948013
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study.
    Lim HS; Kim SJ; Noh YH; Lee BC; Jin SJ; Park HS; Kim S; Jang IJ; Kim SE
    Pharm Res; 2013 Mar; 30(3):683-93. PubMed ID: 23138261
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dopamine D
    Vanover KE; Davis RE; Zhou Y; Ye W; Brašić JR; Gapasin L; Saillard J; Weingart M; Litman RE; Mates S; Wong DF
    Neuropsychopharmacology; 2019 Feb; 44(3):598-605. PubMed ID: 30449883
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA.
    Finnema SJ; Halldin C; Bang-Andersen B; Gulyás B; Bundgaard C; Wikström HV; Farde L
    Synapse; 2009 May; 63(5):378-89. PubMed ID: 19173265
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.
    Catafau AM; Suarez M; Bullich S; Llop J; Nucci G; Gunn RN; Brittain C; Laruelle M;
    Neuroimage; 2009 Jun; 46(2):447-58. PubMed ID: 19233294
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.
    Wong YC; Ilkova T; van Wijk RC; Hartman R; de Lange ECM
    Eur J Pharm Sci; 2018 Jan; 111():514-525. PubMed ID: 29106979
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors.
    Ishiwata K; Oda K; Sakata M; Kimura Y; Kawamura K; Oda K; Sasaki T; Naganawa M; Chihara K; Okubo Y; Ishii K
    Ann Nucl Med; 2006 Oct; 20(8):569-73. PubMed ID: 17134027
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.
    Seneca N; Zoghbi SS; Skinbjerg M; Liow JS; Hong J; Sibley DR; Pike VW; Halldin C; Innis RB
    Synapse; 2008 Oct; 62(10):756-63. PubMed ID: 18651641
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A data driven method for estimation of B(avail) and appK(D) using a single injection protocol with [¹¹C]raclopride in the mouse.
    Wimberley CJ; Fischer K; Reilhac A; Pichler BJ; Gregoire MC
    Neuroimage; 2014 Oct; 99():365-76. PubMed ID: 24862069
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.
    Tateno A; Sakayori T; Kim WC; Honjo K; Nakayama H; Arakawa R; Okubo Y
    Int J Neuropsychopharmacol; 2018 Jun; 21(6):522-527. PubMed ID: 29346639
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacological MRI responses of raclopride in rats: The relationship with D2 receptor occupancy and cataleptic behavior.
    Masaki Y; Kashiwagi Y; Rokugawa T; Ito M; Iimori H; Abe K
    Synapse; 2020 Dec; 74(12):e22180. PubMed ID: 32644234
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.
    Shotbolt P; Tziortzi AC; Searle GE; Colasanti A; van der Aart J; Abanades S; Plisson C; Miller SR; Huiban M; Beaver JD; Gunn RN; Laruelle M; Rabiner EA
    J Cereb Blood Flow Metab; 2012 Jan; 32(1):127-36. PubMed ID: 21878947
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of Dopamine D
    Schildt A; de Vries EFJ; Willemsen ATM; Giacobbo BL; Moraga-Amaro R; Sijbesma JWA; van Waarde A; Sossi V; Dierckx RAJO; Doorduin J
    Mol Pharm; 2020 Mar; 17(3):865-872. PubMed ID: 32011892
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
    Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
    Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.